LENZ Therapeutics to Present at Upcoming Investor Conferences

Company Overview - LENZ Therapeutics, Inc. is a pre-commercial biopharmaceutical company focused on developing and commercializing the first and only aceclidine-based eye drop aimed at improving near vision in individuals with presbyopia [3] - The product candidate, LNZ100, is a preservative-free, single-use, once-daily eye drop containing aceclidine [3] - Presbyopia affects an estimated 1.8 billion people globally and 128 million people in the United States [3] Upcoming Events - Company management will participate in several investor conferences, including: - William Blair 45 Annual Growth Stock Conference on June 3, 2025, in Chicago, IL, with a management presentation at 1:40pm EDT [1] - Jefferies Global Healthcare Conference on June 4-5, 2025, in New York City, NY, with a management presentation at 9:55am EDT [2] - Goldman Sachs 46 Annual Global Healthcare Conference on June 9, 2025, in Miami Beach, FL, featuring a fireside chat at 4:00pm EDT [2] - Live audio webcasts of the presentations will be available on the LENZ Therapeutics website, with replays accessible for 12 months following the events [2] Regulatory Milestones - The U.S. Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) target action date of August 8, 2025, for LNZ100 [3] - The company is committed to commercializing an effective pharmaceutical solution for presbyopia that enhances vision for "all eyes, all day" [3]